Print this page
-
A Phase 3 Trial of Fianlimab (Anti-Lag-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-Risk Melanoma.
Protocol: 092204Principal Investigator:
- Adam Berger (Rutgers University)
Applicable Disease Sites: Melanoma, Skin -
Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma.
Protocol: 092202Principal Investigator:
- Adam Berger (Rutgers University)
Applicable Disease Sites: Melanoma, Skin